Wednesday, February 12, 2020 Daily Archives

MilliporeSigma looks to ‘ReForm’ bioformulations with excipient collaboration

by

MilliporeSigma has teamed with ReForm Biologics to develop and license excipients for use in biologic formulations. The agreement will see the life science business of Germany’s Merck KGaA – known as MilliporeSigma in North America – access proprietary excipients from ReForm Biologics. The bioprocess vendor will fund the development of these excipients for use in the formulation of biological drugs, as well as take charge of manufacturing and commercializing them. “The parties have agreed to keep the exact terms to…

February 12, 2020

Catalent’s $315m Masthercell buy: Frothy exuberance or the new CMO norm?

by

Catalent has completed its $315 million takeover of cell therapy manufacturer Masthercell. But is this latest CMO acquisition a sign of frothy exuberance, or consolidation of the new normal? Dark Horse Consulting’s Anthony Davies thinks the latter. Last week, Catalent announced it had entered into an agreement to buy Orgenesis’ third-party cell and gene therapy business Masthercell for $315 million (€285 million). Yesterday the deal closed, bringing autologous and allogeneic cell therapy manufacturing and analytical services to Catalent’s capabilities. The…

February 12, 2020

Dupixent growth increases Regeneron’s manufacturing costs (again)

by

Regeneron says higher Dupixent (dupilumab) sales drove an increase in manufacturing and collaboration costs in Q4. In the US, Dupixent brought in revenue of $605 million (€554 million) in the final three months of 2019, up 136% on the comparable period a year earlier. Similarly, global net sales of the drug in the fourth quarter increased to $752 million, up from $319 million in 2018. Regeneron senior vice president Marion McCourt told analysts: “We continue to see strong prescribing trends…

February 12, 2020